Skip to main content

Exiqon to Sell Calif. CLIA Lab to Gain 'Efficiencies,' Free Up Resources

Premium

Exiqon announced that it will divest its California-based clinical laboratory improvement amendments-certified lab Oncotech to trim costs.

In late 2007, Exiqon announced it was acquiring Oncotech, a provider of molecular oncology testing services, for $45 million as part of an effort to build up its infrastructure and expertise to begin selling microRNA-based diagnostics (see RNAi News, 11/29/2007).

"Since the acquisition, Exiqon has successfully strengthened its product portfolio for in vitro diagnostics by adding new molecular tests … and other tools to help physicians improve cancer treatment selection," the company said this week. "Exiqon has now decided to consolidate its ongoing development of diagnostic products based on miRNA at the company's facilities in Denmark in order to gain operational and infrastructural efficiencies and to free up human and financial resources."

"This decision will help us focus on our core competencies in the area of miRNA and drive operational synergies between our two business areas, diagnostics and life sciences," Exiqon President and CEO Lars Kongsbak added in a statement.

The company said that as a result of the planned divestiture, it will seek partners to co-develop and commercialize its miRNA-based diagnostics.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.